Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia
- 26 July 2012
- book chapter
- review article
- Published by Springer Science and Business Media LLC in Handbook of Experimental Pharmacology
- No. 213,p. 81-111
- https://doi.org/10.1007/978-3-642-25758-2_4
Abstract
Current antipsychotic medications do little to improve real-life function in most schizophrenia patients. A dispassionate view of the dispersed and variable neuropathology of schizophrenia strongly suggests that it is not currently, and may never be, correctable with drugs. In contrast, several forms of cognitive therapy have been demonstrated to have modest but lasting positive effects on cognition, symptoms, and functional outcomes in schizophrenia patients. To date, attempts to improve clinical outcomes in schizophrenia by adding pro-cognitive drugs to antipsychotic regimens have had limited success, but we propose that a more promising strategy would be to pair drugs that enhance specific neurocognitive functions with cognitive therapies that challenge and reinforce those functions. By using medications that engage spared neural resources in the service of cognitive interventions, it might be possible to significantly enhance the efficacy of cognitive therapies. We review and suggest several laboratory measures that might detect potential pro-neurocognitive effects of drugs in individual patients, using a “test dose” design, aided by specific biomarkers predicting an individual’s drug sensitivity. Lastly, we argue that drug classes viewed as “counter-intuitive” based on existing models for the pathophysiology of schizophrenia—including pro-catecholaminergic and NMDA-antagonistic drugs—might be important candidate “pro-cognitive therapy” drugs.This publication has 145 references indexed in Scilit:
- Peripheral biomarkers of cognitive response to dopamine receptor agonist treatmentPsychopharmacology, 2010
- Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia PatientsBiological Psychiatry, 2010
- Altering Cortical Connectivity: Remediation-Induced Changes in the White Matter of Poor ReadersNeuron, 2009
- Dorsolateral Prefrontal Cortex Activity Predicts Responsiveness to Cognitive–Behavioral Therapy in SchizophreniaBiological Psychiatry, 2009
- Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic SubjectsBiological Psychiatry, 2009
- Pramipexole effects on startle gating in rats and normal menPsychopharmacology, 2009
- Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment responseSynapse, 2009
- Amphetamine effects on startle gating in normal women and female ratsPsychopharmacology, 2009
- Realistic expectations of prepulse inhibition in translational models for schizophrenia researchPsychopharmacology, 2008
- Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophreniaNeurotoxicity Research, 2008